Teva, AZ Want Conspiracy Lawsuit Tossed, Citing Generic Exclusivity Blocking Entry

Drug Industry Daily
Teva and AstraZeneca want a consolidated class action lawsuit alleging they conspired to delay generic entry of AstraZeneca’s acid-reflux drug Nexium dismissed, arguing that Teva couldn’t have marketed its version sooner due to approval delays plaguing Ranbaxy, which has 180 days of generic exclusivity on the product.

To View This Article:


Subscribe To Drug Industry Daily